Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block

Journal Article (Journal Article)

Sodium–glucose cotransporter-2 (SGLT2) inhibitors recently emerged as an effective therapy for heart failure (HF) with reduced ejection fraction. Recent published clinical trials have confirmed these agents substantially reduce mortality and HF hospitalization among patients with established HF with reduced ejection fraction, with or without type 2 diabetes. Ongoing studies are evaluating the effects of SGLT2 inhibitors on clinical outcomes for patients with HF with preserved ejection fraction. Nurse practitioners must understand the indications and mechanisms of SGLT2 inhibitors when prescribing. Thoughtful collaboration between cardiology and endocrine providers can guide management with the use of SGLT2 inhibitors in complicated HF patients.

Full Text

Duke Authors

Cited Authors

  • McDermott, J; Tennyson, C; Bell-McClure, E

Published Date

  • January 1, 2021

Published In

International Standard Serial Number (ISSN)

  • 1555-4155

Digital Object Identifier (DOI)

  • 10.1016/j.nurpra.2021.02.008

Citation Source

  • Scopus